Rui Avelar Sells 29,996 Shares of Evolus (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 29,996 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider owned 430,542 shares in the company, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Rui Avelar also recently made the following trade(s):

• On Monday, December 22nd, Rui Avelar sold 2,261 shares of Evolus stock. The shares were sold at an average price of $7.15, for a total transaction of $16,166.15.

Evolus Stock Up 0.6%

Evolus stock opened at $4.86 on Friday. The company’s fifty day simple moving average is $4.81 and its 200-day simple moving average is $6.08. Evolus, Inc. has a 12 month low of $4.09 and a 12 month high of $13.66. The stock has a market cap of $316.19 million, a P/E ratio of -6.00 and a beta of 1.02.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The firm had revenue of $90.30 million for the quarter, compared to analyst estimates of $89.58 million. On average, equities research analysts expect that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Manchester Capital Management LLC bought a new stake in shares of Evolus in the second quarter valued at about $26,000. State of Alaska Department of Revenue acquired a new position in Evolus in the 3rd quarter valued at approximately $26,000. Larson Financial Group LLC raised its holdings in Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus in the 4th quarter worth approximately $34,000. Finally, Wexford Capital LP bought a new stake in shares of Evolus in the 3rd quarter worth approximately $37,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on EOLS shares. Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. HC Wainwright dropped their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Finally, Mizuho set a $15.00 target price on shares of Evolus in a research note on Wednesday, February 4th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Evolus has a consensus rating of “Moderate Buy” and an average price target of $16.00.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.